Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
9/10
Growth Score
6/10
Valuation Score
5/10
Momentum Score
2/10
₹1,10,437 Cr
19.84
3.74
46.59
0.01
20.71 %
--
0.6 %
1768.37
334
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
| 14.04 | -0.74 | -1.60 | 21.09 | 10.06 | 20.05 | 8.46 |
|
BSE Sensex
| 13.26 | -1.29 | 1.62 | 23.44 | 10.10 | 16.45 | 12.00 |
|
BSE Healthcare
| 41.84 | 0.99 | 16.54 | 58.12 | 19.17 | 29.56 | 12.67 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Dr. Reddy'S Labs
| 36.82 | -13.64 | -6.38 | 80.77 | 10.26 | 8.83 | -21.11 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
₹1,10,437.49 Cr
₹28,949.30 Cr
₹5,565.30 Cr
₹6,132.70 Cr
₹2,002.00 Cr
26.65%
High
₹5,205.55 - 7,107.45
₹5.00
16,68,76,946
BSE: 500124, NSE: DRREDDY
Hyderabad, Telangana
www.drreddys.com
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The... company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
The total asset value of Dr Reddy's Laboratories Ltd stood at ₹ 38,864 Cr as on 30-Jun-24
The share price of Dr Reddy's Laboratories Ltd is ₹6,611.65 (NSE) and ₹6,617.90 (BSE) as of 15-Oct-2024 IST. Dr Reddy's Laboratories Ltd has given a return of 10.06% in the last 3 years.
Dr Reddy's Laboratories Ltd has a market capitalisation of ₹ 1,10,437 Cr as on 15-Oct-2024. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Dr Reddy's Laboratories Ltd is 3.74 times as on 15-Oct-2024, a 45% discount to its peers’ median range of 6.85 times.
The P/E ratio of Dr Reddy's Laboratories Ltd is 19.84 times as on 15-Oct-2024, a 57% discount to its peers’ median range of 46.59 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Dr Reddy's Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Dr Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
The prominent promoters of Dr. Reddy's Laboratories Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
G V PRASAD |
11.52%
|
|
SATISH REDDY KALLAM |
9.61%
|
|
KALLAM SATISH REDDY HUF |
3.31%
|
The chairman of the company is K Satish Reddy, and the managing director is GV Prasad.
There is no promoter pledging in Dr Reddy's Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,56,342
|
|
|
1,28,832
|
|
|
1,18,378
|
|
|
1,11,956
|
| Dr. Reddy's Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
20.71
|
|
Operating margin(%)
|
22.44
|
|
Net Margin(%)
|
18.58
|
|
Dividend yield(%)
|
0.6
|
Yes, TTM profit after tax of Dr Reddy's Laboratories Ltd was ₹5,565 Cr.
₹-48.25
